Exact Sciences (NASDAQ:EXAS) Price Target Raised to $90.00 at TD Cowen

Exact Sciences (NASDAQ:EXAS) had its target price upped by TD Cowen from $74.00 to $90.00 in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the medical research company’s stock.

Several other equities research analysts have also recently issued reports on the stock. Guggenheim raised their price target on shares of Exact Sciences from $70.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday. Cowen reissued a “buy” rating on shares of Exact Sciences in a research note on Tuesday. Wells Fargo & Company set a $68.00 target price on shares of Exact Sciences in a research report on Wednesday, October 1st. Benchmark boosted their price target on Exact Sciences from $60.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wall Street Zen raised Exact Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $72.90.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $69.59 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. The business’s fifty day moving average price is $56.85 and its two-hundred day moving average price is $53.02. The stock has a market cap of $13.17 billion, a PE ratio of -12.82, a price-to-earnings-growth ratio of 5.56 and a beta of 1.24. Exact Sciences has a one year low of $38.81 and a one year high of $72.83.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.11. The business had revenue of $850.74 million for the quarter, compared to the consensus estimate of $810.42 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The business’s revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.21) earnings per share. Exact Sciences has set its FY 2025 guidance at EPS. On average, analysts forecast that Exact Sciences will post -0.58 EPS for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other news, Director James Edward Doyle sold 2,000 shares of the firm’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $60.00, for a total value of $120,000.00. Following the transaction, the director directly owned 57,962 shares in the company, valued at $3,477,720. This trade represents a 3.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Larson Financial Group LLC grew its stake in Exact Sciences by 2,804.8% during the first quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock worth $26,000 after buying an additional 589 shares during the period. National Pension Service lifted its holdings in shares of Exact Sciences by 75.1% during the 1st quarter. National Pension Service now owns 681 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 292 shares in the last quarter. SVB Wealth LLC purchased a new stake in Exact Sciences during the 1st quarter worth $30,000. True Wealth Design LLC boosted its position in Exact Sciences by 951.8% during the 2nd quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after purchasing an additional 533 shares during the period. Finally, Westside Investment Management Inc. increased its holdings in Exact Sciences by 100.0% in the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 271 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.